| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000041445 |
| Receipt No. | R000047311 |
| Scientific Title | Effects of a functional water intake on peripheral blood flow and autonomic nervous system |
| Date of disclosure of the study information | 2022/03/31 |
| Last modified on | 2022/05/02 (Ver. 4) |
| Basic information | ||
| Public title | Effects of a functional water intake on peripheral blood flow and autonomic nervous system | |
| Acronym | Effects of a functional water intake on peripheral blood flow and autonomic nervous system | |
| Scientific Title | Effects of a functional water intake on peripheral blood flow and autonomic nervous system | |
| Scientific Title:Acronym | Effects of a functional water intake on peripheral blood flow and autonomic nervous system | |
| Region |
|
|
| Condition | |||
| Condition | healthy person | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To verify the effects of a functional water intake on peripheral blood flow and autonomic nervous system. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Comparison of peripheral blood flow and function of the autonomic nerve function before and after the intake of a functional water. |
| Key secondary outcomes | Comparison of subjective mood and arousal level before and after the intake of a functional water. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Dose comparison |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of the test drink A (once a test day) | |
| Interventions/Control_2 | Intake of the test drink B (once a test day) | |
| Interventions/Control_3 | Intake of the placebo drink (once a test day) | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Healthy persons who are aged from 20 to 49 years.
2. Persons who are full-time worker on the day shift. 3. Persons who can give written informed consents. |
|||
| Key exclusion criteria | 1. Persons who have previous history such as neurological disorder, nervous system disorder, cardiovascular disease, and other serious disease.
2. Persons who have previous history of nervous system disease such as unconsciousness, coma, convulsion, etc. 3. Persons who have current history of peptic ulcer. 4. Persons with the life support equipment such as cardiac pacemaker. 5. Persons who are in treatment. 6. Persons who usually take in health foods and supplements. 7. Persons who have food allergy. 8. Persons who have vision disorder or auditory disorder. 9. Persons who are pregnant or breastfeed. 10. Persons who cannot drink soda. 11. Persons who are now participating in other clinical trials or participated in other clinical trials within a month before obtaining his/her informed consent in this trial. 12. Persons who are judged not suitable to participate in this trial by investigators. |
|||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | RIKEN | ||||||
| Division name | Laboratory for Pathophysiological and Health Science | ||||||
| Zip code | 650-0047 | ||||||
| Address | 6-7-1 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, JAPAN | ||||||
| TEL | 078-569-8868 | ||||||
| kyosuke.watanabe@riken.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | RIKEN | ||||||
| Division name | Laboratory for Pathophysiological and Health Science | ||||||
| Zip code | 650-0047 | ||||||
| Address | 6-7-1 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, JAPAN | ||||||
| TEL | 078-569-8868 | ||||||
| Homepage URL | |||||||
| kyosuke.watanabe@riken.jp | |||||||
| Sponsor | |
| Institute | RIKEN |
| Institute | |
| Department | |
| Funding Source | |
| Organization | ASAHI SOFT DRINKS CO., LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | RIKEN |
| Address | 2-2-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, JAPAN |
| Tel | 078-306-3036 |
| kobe-ankan@cdb.riken.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047311 |